An icon of a traditional telephone receiver. An icon of a tick mark. An icon of a human eye and eyelashes. An icon of a human eye and eyelashes with a diagonal line through it. A two-lined pause ...

An icon of a traditional telephone receiver. An icon of a tick mark. An icon of a human eye and eyelashes. An icon of a human eye and eyelashes with a diagonal line through it. A two-lined pause ...

David Johansen, the gravelly-voiced singer, was last surviving member of the glam and protopunk band the New York Dolls.

New Mexico authorities say preliminary autopsy results didn't determine how Oscar-winner Gene Hackman and his wife died, but ...

An icon in the shape of a lightning bolt ... especially as the use of GLP-1 drugs surges. Fay said at its launch that the explosion of GLP-1s had boosted demand for registered dietitians as ...

Next to the eye-shaped icon that indicates viewers ... In recent years, her freelancing has focused on drug use and the overdose crisis, with pieces appearing in Vanity Fair, WIRED, The New ...

Choose from Drugs Icon Solid stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...

Choose from Alcohol And Drugs Icon stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection ...

Justin Bieber has been battling an emotional storm behind the scenes, with sources close to the pop star telling ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Luxturna, a gene therapy for a rare disorder that causes vision loss, costs $425,000 per eye. Industry insiders assumed Zolgensma would cost more than Luxturna. But how much? How drug companies ...